A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication

Familial Hypercholesterolemia Clinical Trial

Official title:

A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCentre Study of Colesevelam as Add-on Therapy in Patients With Familial Hypercholesterolaemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00655265
• Other study ID #: CHOL00107
• Secondary ID: EudraCT 2007-000
• Status: Completed
• Phase: Phase 4
• First received: April 3, 2008
• Last updated: February 10, 2014
• Start date: August 2007
• Est. completion date: October 2009

Study information

• Verified date: February 2014
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Sweden: Medical Products AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess whether colesevelam given as third line treatment added to a maximal tolerated and stable dose of a statin and ezetimibe is able to further decrease the level of LDL cholesterol in a safe and efficient manner in difficult to treat Familial Hypercholesterolaemia patients who are not at their target level of LDL cholesterol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 86
• Est. completion date: October 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients must have a clinical diagnosis of Familial Hypercholesterolaemia defined as EITHER a.Presence of a documented LDL-receptor mutation OR b. History of untreated LDL-cholesterol level above the 95th percentile for sex and age in combination with documentation of at least one of the following: i.Presence of typical tendon xanthomas in the patient or first degree relative. ii. An LDL-cholesterol level above the 95th percentile for age and sex in a first degree relative. iii. Proven coronary artery disease in the patient or in a first degree relative under the age of 60.

• Patients must have provided and undergone lifestyle changes for more than 6 months at the time of Screening

• Patients must have been treated for at least 3 consecutive months preceding the Screening visit with a lipid lowering treatment regimen consisting of maximal tolerated combination of a statin with ezetimibe and are still above their target for LDL cholesterol being 2.5 mmol/L (100 mg/dL)

• Patients must be committed to following the protocol requirements as evidence by written informed consent

• Patients should be comfortable with swallowing 3 placebo tablets

Exclusion Criteria:

• Patients with a known allergy to any of the components used in colesevelam or placebo or any other medications like statin or ezetimibe required for participation in this study

• Patients with a bowel or biliary obstruction

• Patients with secondary causes of hypercholesterolaemia, e.g., dysproteinaemia, hypothyroidism, nephrotic syndrome (defined as proteinuria >2 g/L), obstructive liver disease, other pharmacological therapies, alcoholism

• Patients with triglyceride level of > 3.4 mmol/L

• Patients with dysphagia, swallowing disorders, severe gastrointestinal motility disorders, inflammatory bowel disease, or major gastrointestinal tract surgery

• Patients have undergone LDL-apheresis within one year prior to the screening visit and/or need to undergo LDL-apheresis

• Patients with active liver disease or unexplained persistent elevations in transaminases

• Patients on fenofibrates or on concomitant cholestyramine as this will affect the area under the curve (AUC) of ezetimibe

• Patients with poorly-controlled diabetes (i.e., HbA1c>9% at Screening)

• Patients with clinically significant (CS) abnormal haematology, renal, or other laboratory parameters that could be the result of an underlying malignancy or systemic infection as judged by the investigator

• Patients with a heart transplant, concurrent congestive heart failure (NYHA Class 3 or 4), life-threatening ventricular arrhythmias, unstable angina, recent myocardial infarction within the past 6 months prior to screening, or patients undergoing haemodialysis, or with active disease who may not be healthy enough to successfully complete all protocol requirements

• Fertile women who are pregnant, nursing or using either no or an inadequate form of contraception taking into account the recommendations for adequate intake of oral contraceptives as outlined in concomitant medication section

• Patients with a recent history of alcoholism or drug abuse, or sever emotional behavioural or psychiatric problems who may not be able to adequately comply with the requirements of the study or who may be unable to consent

• Patients receiving experimental medications or participating in another study using an experimental drug or procedure within 30 days prior to signing informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II

Intervention

Drug:
• Colesevelam hydrochloride film-coated tablets
tablets
• Placebo
Tablets

Locations

Country	Name	City	State
France	Service d'Endocrinologie, Metabolisme Prevention des Maladies Cardio-Vasculaires	Paris Cedex
Germany	Kardiologie	Marburg
Netherlands	Academic Medical Centre	Amsterdam
Netherlands	University Medical Centre	Nijmegen
Netherlands	University Medical Centre	Utrecht
Netherlands	TweeSteden Ziekenhius	Waalwijk
Sweden	Centre for Metabolism and Endocrinology	Huddinge
United Kingdom	Department of Medicine, University of Manchester	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Countries where clinical trial is conducted

France,  Germany,  Netherlands,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative reduction in LDL cholesterol		Between baseline and 6 weeks DB treatment	No
Secondary	Relative reduction in HDL, total cholesterol, ApoA1,ApoB,ApoB/ApoA1ratio, triglycerides		Between Baseline and week 6 and week 12 DB treatment	No
Secondary	Relative reduction in LDL cholesterol		Between Baseline and week 12 DB treatment	No